KLOW Peptide: What KPV Adds to a Repair Blend

LynxLab · 24 October 2026 · 7 min read

KPV is the three-amino-acid tail of alpha-MSH. What the colitis and cell studies show about it, and why an anti-inflammatory peptide sits inside the KLOW blend.

Photo: CDC, Unsplash

KLOW is four peptides in one 80mg vial: KPV, BPC-157, TB-500 and GHK-Cu. Three of them are the repair-focused components of the GLOW blend, and the fourth, KPV, is different in kind. It is not studied as a growth or collagen peptide at all; its literature is about inflammation, and this post looks at why an anti-inflammatory tripeptide ends up in a skin-repair blend.

What KPV is

KPV is a tripeptide: lysine, proline, valine. It is the carboxy-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), residues 11 to 13 of that 13-amino-acid hormone, which is why older papers call it alpha-MSH(11-13).

Alpha-MSH itself is cut from the precursor pro-opiomelanocortin and is made by pituitary cells, monocytes, melanocytes and keratinocytes. Cutuli and colleagues (Journal of Leukocyte Biology, 2000) summarised the earlier work in one line: the anti-inflammatory "message sequence" of alpha-MSH resides in the KPV tripeptide, which has anti-inflammatory effects in vivo and in vitro that parallel the parent molecule.

That is the attraction for researchers. A three-residue fragment that carries the anti-inflammatory activity of a hormone, without the pigmentation signal that sits elsewhere in the sequence. The kpv literature is therefore almost entirely about inflammation, not about colour.

The colitis studies that made KPV's name

The two most cited KPV papers both appeared in 2008 and both used mouse models of inflammatory bowel disease.

Dalmasso and colleagues (Gastroenterology, 2008) worked out how the peptide gets into cells. In human intestinal epithelial lines and Jurkat T cells, nanomolar concentrations of KPV inhibited activation of NF-kappaB and MAP kinase signalling and reduced pro-inflammatory cytokine secretion. They showed the peptide is carried into cells by PepT1, a di- and tripeptide transporter that is normally confined to the small intestine but switches on in the colon during inflammation. In mice, KPV in drinking water reduced the incidence of colitis induced by DSS and TNBS.

Kannengiesser and colleagues (Inflammatory Bowel Diseases, 2008) tested KPV in DSS colitis and in a T-cell transfer colitis model. Treated mice recovered earlier, regained weight faster and showed less inflammatory infiltrate and lower myeloperoxidase activity in colon tissue. The striking detail is what happened in mice with a non-functional melanocortin-1 receptor: KPV still rescued every animal in the treated group from death during DSS colitis. The authors concluded the effect is "at least partially independent of MC1R signaling".

Both are animal and cell studies. There is no published human trial of KPV for any indication.

The pathways involved

Brzoska, Luger and colleagues reviewed alpha-MSH and its tripeptides in Endocrine Reviews in 2008. At the molecular level, they listed the targets: NF-kappaB activation, expression of adhesion molecules and chemokine receptors, production of pro-inflammatory cytokines, IL-10 synthesis, T-cell proliferation, inflammatory cell migration, antioxidant enzyme expression and apoptosis.

NF-kappaB is the common thread. It is the transcription factor that switches on most of the genes behind an inflammatory response, and both the Dalmasso and the Brzoska papers put KPV's effect on that switch.

The review also noted that alpha-MSH acts on skin cells directly, through melanocortin receptors on keratinocytes and other peripheral cell types. That is the hook for skin researchers who want to buy klow rather than the three-peptide blend: the inflammatory signalling that KPV touches is active in the dermis and epidermis, not only in the gut.

An antimicrobial footnote

Cutuli's 2000 paper asked a different question. Corticosteroids and non-steroidal anti-inflammatories reduce the killing of pathogens, so the authors tested whether alpha-MSH and its fragments did the same. They examined alpha-MSH(1-13), (6-13) and (11-13) against Staphylococcus aureus, including a methicillin-resistant strain, and Candida albicans, and reported antimicrobial rather than immunosuppressive effects in the title of their paper.

The finding has not been pursued in a clinical setting, but it addresses an obvious worry about putting an anti-inflammatory into a wound-repair blend: that damping inflammation might also damp defence against infection. In this one in-vitro study, the tripeptide did not behave like a steroid.

Why add an anti-inflammatory to a repair blend

Huang and colleagues (2015), writing about BPC-157 burn healing, divided repair into four phases: haemostasis, inflammation, proliferation and remodelling. The three GLOW peptides are studied against the last two. BPC-157 has rat data on angiogenesis and burn closure, the thymosin beta-4 fragment TB-500 has data on keratinocyte migration and re-epithelialisation, and GHK-Cu has fibroblast collagen data going back to 1988.

The inflammation phase is the gap. A 2026 systematic review of GHK-Cu did list anti-inflammatory action among its preclinical effects, but none of the three is primarily an inflammation peptide. KPV is. Adding it to the blend is a hypothesis that a model of skin repair should address the inflammatory phase as well as the proliferative and remodelling ones.

It is a hypothesis, not a result. No study has tested KPV together with any of the other three, in skin or anywhere else. A researcher who orders a klow peptide blend is buying a fixed-ratio reagent to test that idea, not a proven combination.

What is known about KPV's safety and status

Very little in humans. The FDA's category 2 list of bulk drug substances states that the agency "has not identified any human exposure data on drug products containing KPV administered via any route of administration" and that it lacks important information on any safety issues the peptide might raise. On that basis KPV sits in category 2 alongside BPC-157, TB-500 and injectable GHK-Cu, and cannot be compounded in US pharmacies.

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend KPV, BPC-157 and TB-500 for the 503A list, against the written advice of agency scientists. The vote is non-binding and no rule has followed.

In the UK, KPV is not a licensed medicine and the klow peptide vial that contains it is sold for laboratory research only. LynxLab stocks KLOW for research use as an 80mg blend vial at £79.99, with every component tested to 99% purity and the lab report on the product page.

Choosing between the four-peptide and three-peptide blend

The decision comes down to the research question. A model that isolates collagen deposition or endothelial migration has no need for an inflammation peptide and is better served by the three-component GLOW blend, which keeps one variable fewer.

A model that includes an inflammatory insult, such as a burn, an irritant or a bacterial challenge, is where KPV's literature becomes relevant. The companion post on KLOW versus GLOW sets the two side by side, including the arithmetic of the 70mg and 80mg vials.

The batch lab reports for both blends are published, and the klow 80mg certificate reports KPV as its own peak with its own purity figure.

Frequently asked questions

What does KPV stand for?

KPV is the single-letter code for its three amino acids: K for lysine, P for proline, V for valine. It is the carboxy-terminal fragment of alpha-melanocyte-stimulating hormone, residues 11 to 13, and older papers call it alpha-MSH(11-13).

Is KPV anti-inflammatory?

In cell and mouse studies, yes. Dalmasso and colleagues (2008) showed nanomolar KPV inhibited NF-kappaB and MAP kinase signalling and reduced colitis in mice, and Kannengiesser and colleagues (2008) saw faster recovery and less tissue inflammation in two colitis models. No human trial has been published.

Why is KPV in the KLOW blend?

The other three components, BPC-157, TB-500 and GHK-Cu, are studied against the proliferation and remodelling phases of repair. KPV is the one component whose literature is about the inflammation phase. Its inclusion is a hypothesis about covering all stages of a repair model, not a tested combination.

Is KPV legal in the UK?

KPV is not a licensed medicine in the UK and, like the KLOW UK vial that contains it, is sold for laboratory research only. In the United States the FDA lists it in category 2 of bulk drug substances, noting no human exposure data, and a July 2026 advisory committee vote to allow compounding has not been acted on.

Sources

Research use only

KLOW from LynxLab

80mg vials from £79.99. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy KLOW